Results 221 to 230 of about 492,732 (252)
Some of the next articles are maybe not open access.
Oral Hydromorphone Extended-Release
The Consultant Pharmacist, 2010To review the chemistry, pharmacodynamics, pharmacokinetics, efficacy, tolerability, dosing, and role of the Osmotic-controlled Release Oral delivery System (OROS) hydromorphone extended-release (ER) tablets.A MEDLINE/PUBMED search (1986-August 2010) was conducted to identify studies in the English language, with additional references being obtained ...
openaire +2 more sources
Drugs, 2012
The extended release (ER; as ascribed in the US) or prolonged release (PR; as ascribed in Europe) formulation (hereafter referred to as ER) of the oral analgesic tapentadol is believed to exert its analgesic effects via μ-opioid receptor agonistic and norepinephrine reuptake inhibitory activity.
openaire +2 more sources
The extended release (ER; as ascribed in the US) or prolonged release (PR; as ascribed in Europe) formulation (hereafter referred to as ER) of the oral analgesic tapentadol is believed to exert its analgesic effects via μ-opioid receptor agonistic and norepinephrine reuptake inhibitory activity.
openaire +2 more sources
Extended-Released Morphine Products
American Journal of Nursing, 1996M, McCaffery, C, Lochmann
openaire +2 more sources
Release mechanisms and applications of drug delivery systems for extended-release
Expert Opinion on Drug Delivery, 2020Renhe Liu, Yao Fu, W John Kao
exaly
Canadian Journal of Health Technologies
The Formulary Management Expert Committee (FMEC) recommends that guanfacine extended release (XR) be reimbursed for the adjunct therapy to psychostimulants for the treatment of attention-deficit/hyperactivity disorder (ADHD) in children and adolescents, aged 6 years to 17 years, whose disease has responded suboptimally to psychostimulants, provided ...
openaire +1 more source
The Formulary Management Expert Committee (FMEC) recommends that guanfacine extended release (XR) be reimbursed for the adjunct therapy to psychostimulants for the treatment of attention-deficit/hyperactivity disorder (ADHD) in children and adolescents, aged 6 years to 17 years, whose disease has responded suboptimally to psychostimulants, provided ...
openaire +1 more source
Extended release of dexamethasone from silicone-hydrogel contact lenses containing vitamin E
Journal of Controlled Release, 2010Anuj Chauhan
exaly

